DRI Healthcare Trust Announces Third Quarter 2026 Financial Results

DRI Healthcare Trust reported third-quarter 2026 total income of $46.9 million and normalized total cash receipts of $47.5 million. It acquired royalty participation rights in Juvmo (tavapadon) for $316 million, its largest transaction to date, and recorded a $14.6 million non-cash impairment on its Zejula royalty asset. Management said the Trust is tracking above the upper end of its 2026–2030 aspirational targets, citing capital redeployment following the Ekterly disposition.